Has Sharath Subramanian, MD received payments from drug or device companies?

Yes. Drug and device makers reported $21,874 in general payments to Sharath Subramanian, MD across 53 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sharath Subramanian, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sharath Subramanian, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sharath Subramanian, MD

Cardiovascular Disease · Saint Cloud, MNNPI 1619047529

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,820 of the $21,874 with a category attached, or 72.3%. Amgen accounts for 72.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $6,632 and has fallen 96.1% since, to $259 in 2025.

$21,874in general payments, 2019–2025

Across 53 payments — averaging $412.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$16K
Edwards Lifesciences$3K
Novartis$2K
Abbott$2K
Boston Scientific$113
Siemens Medical Solutions USA, Inc.$75
plus $134 from 4 others

$380,068in research payments, 2019–2025

Across 28 payments — averaging $13,574 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$228K
Amgen$152K

What the payments were for

Consulting fees$1,5007%
Speaking & faculty fees$15,82072%
Travel & lodging$3,34715%
Food & beverage$1,1945%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	10	$15,825
Edwards Lifesciences	13	$2,526
Novartis	4	$1,640
Abbott	15	$1,560
Boston Scientific	4	$113
Siemens Medical Solutions USA, Inc.	2	$75
Canon Medical Systems USA, Inc.	1	$68
Heartflow, Inc.	2	$41
Cardiac Dimensions, Inc.	1	$14
Regeneron Healthcare Solutions, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Repatha$15,820
LEQVIO$1,608
Edwards SAPIEN 3 Transcatheter Heart Valve$1,015
EVOQUE$873
TRICLIP$122
SAPIEN 3 Ultra RESILIA$101

How this compares

$21,874 in reported general payments places this provider in the 80th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024

$499,400

Medicare patients

2,244

Services billed

36,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Repatha SureclickEvolocumab	582	$782,433
Praluent PenAlirocumab	152	$173,576
EliquisApixaban	39	$55,153
XareltoRivaroxaban	25	$26,656
NexletolBempedoic Acid	23	$21,849
Repatha PushtronexEvolocumab	15	$14,762
Ezetimibe	158	$3,792
Atorvastatin Calcium	193	$2,626
Metoprolol Succinate	106	$2,056
Rosuvastatin Calcium	102	$1,603
Isosorbide Mononitrate ErIsosorbide Mononitrate	33	$735
FenofibrateFenofibrate Nanocrystallized	21	$707
ClopidogrelClopidogrel Bisulfate	25	$587
Losartan Potassium	39	$483
Metoprolol Tartrate	49	$419

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Saint Cloud

Jeffrey ChambersMinneapolis$3.2M
Srijoy MahapatraRochester$1.2M
Markus MeyerMinneapolis$786K
Robert SchwartzMinneapolis$502K
Robert VantasselMinneapolis$493K
Charanjit RihalRochester$478K
Amir LermanRochester$465K
Nedaa SkeikMinneapolis$453K
Joao CavalcanteMinneapolis$384K
Inderjit AnandMinneapolis$384K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →